


Thalidomide-O-amido-C8-NH2

Cat. No.:	HY-107439
CAS No.:	1950635-15-0
Molecular Formula:	C ₂₃ H ₃₀ N ₄ O ₆
Molecular Weight:	458.51
Target:	E3 Ligase Ligand-Linker Conjugate
Pathway:	PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Thalidomide-O-amido-C8-NH2 (Cereblon Ligand-Linker Conjugates 2), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs ^[1] .
IC₅₀ & Target	Cereblon
In Vitro	Thalidomide-O-amido-C8-NH2 is a degron-linker (refer to Compound DL7-TL). The PROTAC linker is bound to at least one targeting ligand. Degron-linker-targeting ligand, wherein the linker is covalently bound to at least one degron and at least one targeting ligand, the degron is a compound capable of binding to an ubiquitin ligase such as an E3 ubiquitin ligase (e.g. cereblon), and the targeting ligand is capable of binding to the targeted protein (s) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Bioconjug Chem. 2020 Nov 18;31(11):2564-2575.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO 2017024317 A2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA